{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:34:13Z","timestamp":1793644453160,"version":"4.5.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.rpth.2026.106849","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:48:04Z","timestamp":1784332084000},"page":"106849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Coagulation potential of concomitant factor VIII administration in people with hemophilia A receiving emicizumab prophylaxis (CAGUYAMA study): a multicenter, open-label, nonrandomized clinical trial"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9348-9815","authenticated-orcid":false,"given":"Masahiro","family":"Takeyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Ogiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ozu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Sasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Furuichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Takase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iyou","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Fukutake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kagehiro","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiai","family":"Nagae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuki","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Higasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhisa","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106849_bib1","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.rpth.2026.106849_bib2","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106849_bib3","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106849_bib4","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2352-3026(22)00377-5","article-title":"Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study","volume":"10","author":"N\u00e9grier","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2026.106849_bib5","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2026.106849_bib6","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/bloodadvances.2017006684","article-title":"Long-term safety and efficacy of emicizumab in a phase 1\/2 study in patients with hemophilia A with or without inhibitors","volume":"1","author":"Shima","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106849_bib7","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors","volume":"25","author":"Shima","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106849_bib8","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106849_bib9","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/jth.14022","article-title":"Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa\/factor X bispecific antibody emicizumab","volume":"16","author":"Nogami","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106849_bib10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12185-019-02698-8","article-title":"Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis","volume":"110","author":"Yada","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.rpth.2026.106849_bib11","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s12185-021-03276-7","article-title":"Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients","volume":"115","author":"Nakajima","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.rpth.2026.106849_bib12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3390\/jcm11030801","article-title":"Current choices and management of treatment in persons with severe hemophilia A without inhibitors: a mini-delphi consensus","volume":"11","author":"Coppola","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.rpth.2026.106849_bib13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12185-020-02959-x","article-title":"A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa\/X","volume":"112","author":"Ogiwara","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.rpth.2026.106849_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29731","article-title":"Heterogeneous coagulant potential of emicizumab in neonatal factor VIII-deficient plasma","volume":"69","author":"Takeyama","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.rpth.2026.106849_bib15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/jth.14746","article-title":"An anti-factor IXa\/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A","volume":"18","author":"Takeyama","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106849_bib16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12185-021-03249-w","article-title":"Comprehensive blood coagulation potential in patients with acquired hemophilia A: retrospective analyses of plasma samples obtained from nationwide centers across Japan","volume":"115","author":"Takeyama","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.rpth.2026.106849_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30590","article-title":"Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A","volume":"70","author":"Takeyama","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.rpth.2026.106849_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-072565","article-title":"Study protocol for assessment of the coagulation potential of concomitantly used factor VIII concentrates in patients with haemophilia A with emicizumab prophylaxis (CAGUYAMA Study): a multicentre open-label non-randomised clinical trial","volume":"13","author":"Takeyama","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.rpth.2026.106849_bib19","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106849_bib20","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.14135","article-title":"Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies","volume":"16","author":"Nogami","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106849_bib21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/hae.14662","article-title":"Anti-idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab","volume":"29","author":"Ogiwara","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106849_bib22","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1055\/s-0041-1725009","article-title":"Ex vivo prediction of comprehensive coagulation potential using simulated blood concentrations of emicizumab in patients with acquired hemophilia A","volume":"121","author":"Takeyama","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106849_bib23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s12185-025-04098-7","article-title":"Emicizumab enhances the ex vivo coagulant potential in plasma samples from patients with von Willebrand disease","volume":"123","author":"Yabe","year":"2025","journal-title":"Int J Hematol"},{"key":"10.1016\/j.rpth.2026.106849_bib24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1365-2516.2003.00762.x","article-title":"The pharmacokinetics of clotting factor therapy","volume":"9","author":"Berntorp","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106849_bib25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/hae.12793","article-title":"Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq\u00ae) in adults with severe haemophilia A: efficacy and safety","volume":"22","author":"Lissitchkov","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106849_bib26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s12185-023-03683-y","article-title":"Emicizumab-mediated hemostatic function assessed by thrombin generation assay in an in vitro model of factor VIII-depleted thrombophilia plasma","volume":"119","author":"Yada","year":"2024","journal-title":"Int J Hematol"},{"key":"10.1016\/j.rpth.2026.106849_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241295653","article-title":"Efficacy of emicizumab in patients with severe haemophilia A without factor VIII inhibitors in Germany: evaluation of real-life data documented by the smart medication eDiary","volume":"15","author":"Escuriola Ettingshausen","year":"2024","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.rpth.2026.106849_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.103164","article-title":"Emicizumab utilization, safety, and outcomes in people with severe hemophilia and no inhibitors: 3-year follow-up. A report from the UK Haemophilia Centre Doctors\u2019 Organisation","volume":"9","author":"Wall","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106849_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/hae.70151","article-title":"Safety and effectiveness of emicizumab in people with haemophilia A enrolled in the ATHN 7 haemophilia natural history study","volume":"32","author":"Buckner","year":"2026","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106849_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-102657","article-title":"NuPOWER (Nuwiq for Perioperative management Of patients With haemophilia A on Emicizumab Regular prophylaxis): protocol for an open-label, single-arm, multicentre study","volume":"15","author":"Srivastava","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.rpth.2026.106849_bib31","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jtha.2022.10.004","article-title":"A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A","volume":"21","author":"Shima","year":"2023","journal-title":"J Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:55:26Z","timestamp":1790164526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926035077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2475037926035077"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106849","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coagulation potential of concomitant factor VIII administration in people with hemophilia A receiving emicizumab prophylaxis (CAGUYAMA study): a multicenter, open-label, nonrandomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106849","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106849"}}